Innovation1 Biotech Net Debt/FCF

What does Innovation1 Biotech do? Innovation1 Biotech, Inc. develops modified Schedule 1 molecules from botanical sources, creating synthetic derivatives for neurologic, psychiatric, dermatologic, and ophthalmologic disorders. The company offers five preclinical prodrugs: a mushroom-derived psychedelic prodrug for PTSD and depression, a cannabinoid and tree bark-derived psychedelic prodrug for addiction, and three cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation. These products are based on synthetic derivatives of natural molecules like psilocin from mushrooms and synthetic tetrahydrocannobivarin from Cannabis, with no botanical sourcing in the final products. The company's clients are pharmaceutical firms seeking novel treatments for complex conditions, focusing on neurologic and psychiatric applications. The first prodrug targets PTSD and depression using a synthetic psilocin derivative, while the second combines cannabinoid and tree bark elements for addiction treatment. The third prodrug addresses pediatric epilepsy, scarring, and eye inflammation through cannabinoid-based synthetic compounds. Innovation1 Biotech's revenue comes from licensing its preclinical compounds to pharmaceutical companies for further development and commercialization, with a focus on high-value therapeutic areas like mental health and rare diseases. The company's portfolio emphasizes synthetic chemistry without reliance on direct botanical extraction for its final drug candidates. Innovation1 Biotech is one of the most popular companies on Eulerpool.